<DOC>
	<DOCNO>NCT00380276</DOCNO>
	<brief_summary>Open-label treatment MPC-7869 participant previous randomize study .</brief_summary>
	<brief_title>Open-Label Treatment With MPC-7869 Patients With Alzheimer 's Who Previously Participated MPC-7869 Protocol</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Flurbiprofen</mesh_term>
	<criteria>Participation previous MPC7869 randomize protocol Have diagnosis probable Alzheimer 's disease . Men woman age 55 year great live community time enrollment ( i.e. , live rest home nursing care facility ) . Signed subject Informed Consent Form willing able participate duration study . Female subject must surgically sterile postmenopausal &gt; 1 year . Subjects must reliable caregiver read , understand speak English Spanish . History evidence , active malignancy , except basal cell carcinoma squamous cell carcinoma skin , within 24 month prior entry . Men prostate cancer may enrol discretion sponsor . Chronic acute renal , hepatic metabolic disorder . Use investigational therapy within 30 day , 5 halflives , whichever longer , and/or use AD immunotherapy prior screening .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>Alzheimer 's</keyword>
	<keyword>Dementia</keyword>
	<keyword>Dementia Alzheimer Type</keyword>
</DOC>